Literature DB >> 21097657

Prevention of autoimmune rheumatic disease: state of the art and future perspectives.

Lars Klareskog1, Peter K Gregersen, Tom W J Huizinga.   

Abstract

Prevention of disease can in principle be accomplished by identification of environmental and/or lifestyle risk and protective factors followed by public health measures (such as for smoking and lung cancer), or by modification of the individual's reactions to disease-inducing factors (such as in vaccinations against microbes). This review discusses both options based on emerging understanding of aetiologies in inflammatory rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The major current opportunity for public health-based prevention lies in avoiding smoking. In RA, recent studies have calculated that, in Sweden (a country characterised by a low frequency of smoking), 20% of all RA cases and 33% of all cases of ACPA-positive RA would not have occurred in a smoke-free society. Smoking is also a major risk factor for SLE but no population attribution is yet available. New avenues for individualised and biology-based prevention are provided by the demonstration that several autoimmune rheumatic diseases are preceded by emergence of subclinical autoimmunity followed by laboratory-based signs of inflammation and finally overt disease. Examples of this process are provided from studies of autoimmunity to citrullinated proteins (in RA), to dsDNA (in SLE in general) and to Ro52 epitopes (in the case of neonatal heart block). The recognition of this sequence of events provides opportunities to intervene specifically and potentially curatively before onset of full-blown disease. Such prevention can be accomplished by modification of inciting antigens (environment), by modification of immunity (more or less specific immunomodulation) or by modification of specific gene functions. In all cases, prevention will be different in different subsets of disease and differ at different time points of disease development. Thus, the road map towards prevention of autoimmune rheumatic diseases includes increased understanding of how genes, environment and immunity interact.

Entities:  

Mesh:

Year:  2010        PMID: 21097657     DOI: 10.1136/ard.2010.142109

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  34 in total

Review 1.  Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis.

Authors:  M Kristen Demoruelle; Kevin D Deane
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

Review 2.  Preclinical systemic lupus erythematosus.

Authors:  Julie M Robertson; Judith A James
Journal:  Rheum Dis Clin North Am       Date:  2014-09-02       Impact factor: 2.670

Review 3.  Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis.

Authors:  Anca I Catrina; Kevin D Deane; Jose U Scher
Journal:  Rheumatology (Oxford)       Date:  2014-12-23       Impact factor: 7.580

Review 4.  Epigenetics in the pathogenesis of RA.

Authors:  Caroline Ospelt; Steffen Gay; Kerstin Klein
Journal:  Semin Immunopathol       Date:  2017-03-21       Impact factor: 9.623

Review 5.  Pre-rheumatoid arthritis and its prevention.

Authors:  Binoy J Paul; Hemanth Illath Kandy; Vinod Krishnan
Journal:  Eur J Rheumatol       Date:  2017-04-11

6.  The presence of FCGR2B promoter or transmembrane region variant alleles leads to reduced serum IL-6 levels in rheumatoid arthritis.

Authors:  Stefanie Meister; Robby Engelmann; Christian Kneitz; Brigitte Müller-Hilke
Journal:  Rheumatol Int       Date:  2015-01-29       Impact factor: 2.631

Review 7.  Targeting mechanisms at sites of complement activation for imaging and therapy.

Authors:  V Michael Holers
Journal:  Immunobiology       Date:  2015-04-30       Impact factor: 3.144

Review 8.  Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences.

Authors:  Axel Finckh; Monica Escher; Matthew H Liang; Nick Bansback
Journal:  Curr Rheumatol Rep       Date:  2016-08       Impact factor: 4.592

Review 9.  Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis.

Authors:  V Michael Holers
Journal:  Curr Opin Immunol       Date:  2013-11-08       Impact factor: 7.486

10.  Regional differences regarding risk of developing rheumatoid arthritis in Stockholm County, Sweden: results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study.

Authors:  H Källberg; V Vieira; M Holmqvist; J E Hart; K H Costenbader; C Bengtsson; L Klareskog; E W Karlson; L Alfredsson
Journal:  Scand J Rheumatol       Date:  2013-04-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.